Commvault Systems Inc vs Revvity Inc — how do they compare? Commvault Systems Inc trades at $154.2 (market cap $6.25B), while Revvity Inc trades at $155.03 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 2.7× Commvault Systems Inc's market cap, and Revvity Inc pays a 0.18% dividend while Commvault Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Revvity Inc for 12 Days on average.
| CVLT | RVTY | |
|---|---|---|
Market Cap | $6.25B | $16.98B |
Volume | 632,727 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $176.52 | $157.36 |
52-Week Low | $75.18 | $82.26 |
Typical Hold Time | 17 Days | 12 Days |
Enterprise Value | $6.24B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $150.74, up 0.31% with strong bullish technical momentum. The stock shows robust earnings performance, beating estimates for three consecutive quarters, with Q3 2026 results pending. Recent business developments include AWS Data Competency achievement and expanded FedRAMP authorization, positioning the company for growth in AI-driven resilience markets.
The outlook remains positive with 54.5% analyst buy ratings and a $156.55 consensus target, though high valuation multiples and declining profit margins warrant caution. Key risks include competitive pressures in cybersecurity and execution challenges in maintaining growth momentum amid expanding AI capabilities.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
Latest headlines on both assets
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →